{"id":62818,"date":"2026-04-10T23:35:15","date_gmt":"2026-04-10T15:35:15","guid":{"rendered":"https:\/\/flcube.com\/?p=62818"},"modified":"2026-04-10T23:35:17","modified_gmt":"2026-04-10T15:35:17","slug":"lynk-pharmaceuticals-jak1-inhibitor-zemprocitinib-enters-nmpa-review-for-atopic-dermatitis","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=62818","title":{"rendered":"Lynk Pharmaceuticals\u2019 JAK1 Inhibitor Zemprocitinib Enters NMPA Review for Atopic Dermatitis"},"content":{"rendered":"\n<p><strong>Lynk Pharmaceuticals Co., Ltd.<\/strong>, a clinical-stage Chinese biopharmaceutical company, announced that the <strong>National Medical Products Administration (NMPA)<\/strong> has formally accepted its <strong>New Drug Application (NDA)<\/strong> for <strong>zemprocitinib<\/strong>, a <strong>second-generation selective JAK1 inhibitor<\/strong>, for the treatment of <strong>moderate-to-severe atopic dermatitis (AD)<\/strong>. The filing is supported by a completed <strong>52-week Phase III clinical trial<\/strong> demonstrating efficacy and safety in AD patients.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-amp-development-status-overview\">Regulatory &amp; Development Status Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Indication<\/th><th>Development Stage<\/th><th>Key Milestone<\/th><\/tr><\/thead><tbody><tr><td><strong>Atopic Dermatitis (AD)<\/strong><\/td><td>NDA under NMPA review<\/td><td>Phase III (52 weeks) completed<\/td><\/tr><tr><td><strong>Rheumatoid Arthritis (RA)<\/strong><\/td><td>Phase III<\/td><td>Dosing extension phase ongoing<\/td><\/tr><tr><td><strong>Ankylosing Spondylitis (AS)<\/strong><\/td><td>Phase III<\/td><td>Patient enrollment active<\/td><\/tr><tr><td><strong>Vitiligo<\/strong><\/td><td>Phase II<\/td><td>Trial initiation in preparation<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>Zemprocitinib\u2019s high selectivity for <strong>JAK1<\/strong> over other JAK family members (JAK2, JAK3, TYK2) is designed to preserve therapeutic efficacy while minimizing off-target safety risks\u2014a key differentiator in an increasingly scrutinized drug class.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-rationale-amp-competitive-positioning\">Clinical Rationale &amp; Competitive Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Unmet Need:<\/strong> Over <strong>80 million<\/strong> people in China suffer from AD, with limited access to safe, long-term systemic therapies<\/li>\n\n\n\n<li><strong>Safety Focus:<\/strong> Next-gen JAK1 inhibitors like zemprocitinib aim to address regulatory concerns raised by earlier pan-JAK agents (e.g., cardiovascular and thrombotic risks)<\/li>\n\n\n\n<li><strong>Dosing Advantage:<\/strong> Once-daily oral regimen with favorable pharmacokinetics observed in trials<\/li>\n\n\n\n<li><strong>Broad Pipeline Strategy:<\/strong> Simultaneous advancement across multiple immune-mediated inflammatory diseases (IMIDs) enhances commercial scalability<\/li>\n<\/ul>\n\n\n\n<p>If approved, zemprocitinib would become one of the first <strong>domestically developed selective JAK1 inhibitors<\/strong> launched in China for AD, competing with global entrants like abrocitinib and upadacitinib.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market Access:<\/strong> Potential inclusion in provincial reimbursement programs given high disease burden<\/li>\n\n\n\n<li><strong>Global Potential:<\/strong> Data package may support future filings with FDA and EMA, particularly if safety profile proves superior<\/li>\n\n\n\n<li><strong>Platform Validation:<\/strong> Success would affirm Lynk\u2019s internal discovery capabilities in kinase-targeted immunology<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory review, clinical development, and commercial prospects. Actual outcomes are subject to NMPA decisions, trial results, and evolving safety guidance for JAK inhibitors.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Lynk Pharmaceuticals Co., Ltd., a clinical-stage Chinese biopharmaceutical company, announced that the National Medical Products&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[65,1351,38],"class_list":["post-62818","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-auto-immune","tag-lynk-pharmaceuticals","tag-market-approval-filings"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Lynk Pharmaceuticals\u2019 JAK1 Inhibitor Zemprocitinib Enters NMPA Review for Atopic Dermatitis - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Lynk Pharmaceuticals Co., Ltd., a clinical-stage Chinese biopharmaceutical company, announced that the National Medical Products Administration (NMPA) has formally accepted its New Drug Application (NDA) for zemprocitinib, a second-generation selective JAK1 inhibitor, for the treatment of moderate-to-severe atopic dermatitis (AD). The filing is supported by a completed 52-week Phase III clinical trial demonstrating efficacy and safety in AD patients.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=62818\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lynk Pharmaceuticals\u2019 JAK1 Inhibitor Zemprocitinib Enters NMPA Review for Atopic Dermatitis\" \/>\n<meta property=\"og:description\" content=\"Lynk Pharmaceuticals Co., Ltd., a clinical-stage Chinese biopharmaceutical company, announced that the National Medical Products Administration (NMPA) has formally accepted its New Drug Application (NDA) for zemprocitinib, a second-generation selective JAK1 inhibitor, for the treatment of moderate-to-severe atopic dermatitis (AD). The filing is supported by a completed 52-week Phase III clinical trial demonstrating efficacy and safety in AD patients.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=62818\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-10T15:35:15+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-10T15:35:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62818#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62818\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Lynk Pharmaceuticals\u2019 JAK1 Inhibitor Zemprocitinib Enters NMPA Review for Atopic Dermatitis\",\"datePublished\":\"2026-04-10T15:35:15+00:00\",\"dateModified\":\"2026-04-10T15:35:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62818\"},\"wordCount\":327,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Auto-immune\",\"Lynk Pharmaceuticals\",\"Market approval filings\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62818#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62818\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=62818\",\"name\":\"Lynk Pharmaceuticals\u2019 JAK1 Inhibitor Zemprocitinib Enters NMPA Review for Atopic Dermatitis - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-10T15:35:15+00:00\",\"dateModified\":\"2026-04-10T15:35:17+00:00\",\"description\":\"Lynk Pharmaceuticals Co., Ltd., a clinical-stage Chinese biopharmaceutical company, announced that the National Medical Products Administration (NMPA) has formally accepted its New Drug Application (NDA) for zemprocitinib, a second-generation selective JAK1 inhibitor, for the treatment of moderate-to-severe atopic dermatitis (AD). The filing is supported by a completed 52-week Phase III clinical trial demonstrating efficacy and safety in AD patients.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62818#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62818\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62818#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lynk Pharmaceuticals\u2019 JAK1 Inhibitor Zemprocitinib Enters NMPA Review for Atopic Dermatitis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Lynk Pharmaceuticals\u2019 JAK1 Inhibitor Zemprocitinib Enters NMPA Review for Atopic Dermatitis - Insight, China&#039;s Pharmaceutical Industry","description":"Lynk Pharmaceuticals Co., Ltd., a clinical-stage Chinese biopharmaceutical company, announced that the National Medical Products Administration (NMPA) has formally accepted its New Drug Application (NDA) for zemprocitinib, a second-generation selective JAK1 inhibitor, for the treatment of moderate-to-severe atopic dermatitis (AD). The filing is supported by a completed 52-week Phase III clinical trial demonstrating efficacy and safety in AD patients.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=62818","og_locale":"en_US","og_type":"article","og_title":"Lynk Pharmaceuticals\u2019 JAK1 Inhibitor Zemprocitinib Enters NMPA Review for Atopic Dermatitis","og_description":"Lynk Pharmaceuticals Co., Ltd., a clinical-stage Chinese biopharmaceutical company, announced that the National Medical Products Administration (NMPA) has formally accepted its New Drug Application (NDA) for zemprocitinib, a second-generation selective JAK1 inhibitor, for the treatment of moderate-to-severe atopic dermatitis (AD). The filing is supported by a completed 52-week Phase III clinical trial demonstrating efficacy and safety in AD patients.","og_url":"https:\/\/flcube.com\/?p=62818","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-10T15:35:15+00:00","article_modified_time":"2026-04-10T15:35:17+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=62818#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=62818"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Lynk Pharmaceuticals\u2019 JAK1 Inhibitor Zemprocitinib Enters NMPA Review for Atopic Dermatitis","datePublished":"2026-04-10T15:35:15+00:00","dateModified":"2026-04-10T15:35:17+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=62818"},"wordCount":327,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Auto-immune","Lynk Pharmaceuticals","Market approval filings"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=62818#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=62818","url":"https:\/\/flcube.com\/?p=62818","name":"Lynk Pharmaceuticals\u2019 JAK1 Inhibitor Zemprocitinib Enters NMPA Review for Atopic Dermatitis - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-10T15:35:15+00:00","dateModified":"2026-04-10T15:35:17+00:00","description":"Lynk Pharmaceuticals Co., Ltd., a clinical-stage Chinese biopharmaceutical company, announced that the National Medical Products Administration (NMPA) has formally accepted its New Drug Application (NDA) for zemprocitinib, a second-generation selective JAK1 inhibitor, for the treatment of moderate-to-severe atopic dermatitis (AD). The filing is supported by a completed 52-week Phase III clinical trial demonstrating efficacy and safety in AD patients.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=62818#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=62818"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=62818#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Lynk Pharmaceuticals\u2019 JAK1 Inhibitor Zemprocitinib Enters NMPA Review for Atopic Dermatitis"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62818","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=62818"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62818\/revisions"}],"predecessor-version":[{"id":62820,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62818\/revisions\/62820"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=62818"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=62818"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=62818"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}